PI3-kinase: from basic cell biology to new cancer therapies
Basic cell biology research at the Babraham Institute is leading to new treatments for cancers, chronic inflammation and other diseases all caused by defects in an important molecular mechanism that transmits signals within a cell and which is controlled by the ‘PI3-kinase’ enzymes.
Since the late 1980s, Babraham scientists have made significant contributions to our knowledge of a class of enzymes called the ‘PI3-kinases’, and to the analytical methods required to study them. Researchers from Babraham now collaborate with, and provide informal consultancy services to, pharmaceutical companies and clinicians interested in developing drugs to treat cancers and other diseases caused by mutations in the PI3-kinase pathway. This was only possible thanks to long-term support for research into the fundamental biology of the PI3-kinase enzymes at the Babraham Institute, which receives strategic funding from BBSRC.